Condition: Myeloproliferative Neoplasms · Sponsor: Incyte Corporation
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital | Phoenix, Arizona, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Mayo Clinic-Florida | Jacksonville, Florida, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Not Yet Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Icahn School of Medicine At Mount Sinai | New York, New York, United States | Recruiting |
| University of North Carolina At Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| South Austin Medical Center | Austin, Texas, United States | Recruiting |
| University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood | Dallas, Texas, United States | Recruiting |
| Huntsman Cancer Institute At University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07008118